Next Article in Journal
Entosis: From Cell Biology to Clinical Cancer Pathology
Next Article in Special Issue
Dopamine D1 Receptor in Cancer
Previous Article in Journal
Genotype of Null Polymorphisms in Genes GSTM1, GSTT1, CYP1A1, and CYP1A1*2A (rs4646903 T>C)/CYP1A1*2C (rs1048943 A>G) in Patients with Larynx Cancer in Southeast Spain
Previous Article in Special Issue
Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors
Review

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge

1
Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, 01323001 São Paulo, Brazil
2
Centro Oncológico Hospital Israelita Albert Eisntein, 05652900 São Paulo, Brazil
3
Baselga Institute of Oncology, Quiron University Hospital Barcelona, 08023 Barcelona, Spain
4
Ramon y Cajal University Hospital, 28034 Madrid, Spain
5
Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain
*
Author to whom correspondence should be addressed.
Received: 8 July 2020 / Revised: 10 August 2020 / Accepted: 14 August 2020 / Published: 1 September 2020
(This article belongs to the Special Issue Hormone Signaling in Cancer)
Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors’ addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level. View Full-Text
Keywords: metastatic breast cancer; CDK4/6 inhibitors; hormone receptor-positive breast cancer metastatic breast cancer; CDK4/6 inhibitors; hormone receptor-positive breast cancer
Show Figures

Figure 1

MDPI and ACS Style

de Melo Gagliato, D.; C Buzaid, A.; Perez-Garcia, J.M.; Llombart, A.; Cortes, J. CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge. Cancers 2020, 12, 2480. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12092480

AMA Style

de Melo Gagliato D, C Buzaid A, Perez-Garcia JM, Llombart A, Cortes J. CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge. Cancers. 2020; 12(9):2480. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12092480

Chicago/Turabian Style

de Melo Gagliato, Debora, Antonio C Buzaid, Jose M. Perez-Garcia, Antonio Llombart, and Javier Cortes. 2020. "CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge" Cancers 12, no. 9: 2480. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12092480

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop